PDS Biotechnology Corp (PDSB): Insider Trading, Congress Trades & Research | Tormere
PDSB
$1.23+5.13%
PDS Biotechnology Corp
Market Cap
$69M
Live price × SEC shares (Aug 6, 2026)
Sector
Health Care
Industry
Biotechnology
Beta (raw)
1.16
60mo monthly vs SPY
P/E (TTM)
N/M
TTM to Jun 2026 · negative earnings
P/S (TTM)
—
Mkt cap / TTM revenue
P/B
N/M
TTM to Jun 2026 · negative equity
EV/EBITDA (TTM)
—
EV / TTM EBITDA
Loading…
Financial Statements
USD thousands
Q3 FY2025
Sep 30, 2025
Q4 FY2025
Dec 31, 2025
Q1 FY2026
Mar 31, 2026
Q2 FY2026
Jun 30, 2026
TTM
Jun 30, 2026
Research & development
4,576
4,406
3,457
3,266
15,705
Total operating expenses
8,140
6,675
6,521
6,497
27,833
Operating income
(8,140)
(6,675)
(6,521)
(6,497)
(27,833)
Interest expense
1,150
1,113
1,015
3,379
6,657
Pretax income
(9,009)
(7,563)
(7,349)
(9,751)
(33,672)
Income tax
0.00
0.00
0.00
0.00
0.00
Net income
(9,009)
(7,563)
(7,349)
(9,751)
(33,672)
EPS (basic) ($)
(0.19)
(0.13)
(0.18)
—
EPS (diluted) ($)
(0.19)
(0.13)
(0.18)
—
Weighted avg. shares (basic)
46,870
55,496
55,660
Weighted avg. shares (diluted)
46,870
55,496
55,660
Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source
Showing the last 5 quarters. 46 more quarters, back to Mar 2014, with Tormere Pro.
